[
    [
        {
            "time": "2018-04-18",
            "original_text": "格隆汇港股聚焦(4.18)︱中国人寿一季度净利润预增80%-100%至243.32亿-270.36亿元",
            "features": {
                "keywords": [
                    "中国人寿",
                    "一季度",
                    "净利润",
                    "预增",
                    "80%-100%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "保险"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(4.18)︱中国人寿一季度净利润预增80%-100%至243.32亿-270.36亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "中信证券：3月社零超预期 建议持续配置消费龙头",
            "features": {
                "keywords": [
                    "中信证券",
                    "社零",
                    "消费龙头"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中信证券：3月社零超预期 建议持续配置消费龙头",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-01",
            "original_text": "生物医药抢跑科创板 最受益的PE/VC排名",
            "features": {
                "keywords": [
                    "生物医药",
                    "科创板",
                    "PE/VC"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "生物医药抢跑科创板 最受益的PE/VC排名",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]